Maze Therapeutics logo
Maze Therapeutics
MAZE | NASDAQ
Chart Builder DCF Calculator
$33.90
-$0.43 (-1.25%)
At close: Nov 16, 2026, 4:00 PM ET
$33.58
-$0.32 (-0.94%)
After-hours: Nov 16, 2026, 7:30 PM ET

Maze Therapeutics Company Profile

Company profile explained

Company Profile

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.

Key Executives

Name Position
Jason V. Coloma Chief Executive Officer & Director
Andrew Good VP & Corporate Controller
Atul Dandekar Chief Strategy & Business Officer
Courtney J. Phillips General Counsel & Corporate Secretary
Harold S. Bernstein President of Research & Development and Chief Medical Officer
Maarten Hoek Chief Scientific Officer
Matt Krause Senior Vice President of Human Resources
Misbah Tahir CFO & Principal Accounting Officer
Nazila Habibizad Senior Vice President of Technical Operations & Supply Chain
Susan Limb Senior Vice President of Clinical Development
Vipin Vijayakumar Senior Vice President of Technology and Business Operations
Winston Tse Senior Vice President of Drug Discovery

Latest SEC Filings

Date Type Title
Oct 30, 2026 4 Filing
Oct 16, 2026 8-K Current Report
Oct 02, 2026 4 Filing
Oct 02, 2026 4 Filing
Oct 01, 2026 4 Filing
Sep 08, 2026 4 Filing
Sep 04, 2026 144 Filing
Sep 04, 2026 4 Filing
Sep 04, 2026 4 Filing
Sep 04, 2026 4 Filing
View All SEC Filings ➞
Maze Therapeutics
Maze Therapeutics logo
Country United States
IPO Date Jan 31, 2025
Industry Biotechnology
Sector Healthcare
Employees 141
CEO Jason Coloma

Contact Details

171 Oyster Point Blvd South San Francisco, California 94080 United States

Stock Details

Ticker Symbol MAZE
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001842295
CUSIP Number 578784100
ISIN Number US5787841007
SIC Code 2836

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.